Magnolia Market Access released its fifth iteration of the IRA Payer Insights Survey in the summer of 2025 to understand how the IRA will affect the Medicare Part D program, including beneficiary premiums, formulary coverage, and contract negotiations for manufacturers and payers.
Find out how one manufacturer turned formulary complexity and policy uncertainty into strategic advantage using Magnolia Market Access’ Part D Formulary Databook.
As Medicare Part D plans adopt stricter utilization management, raise cost-sharing, and adjust tier placements, manufacturers face growing challenges in maintaining access. A data-driven formulary coverage assessment helps teams evaluate product positioning, benchmark competitors, and prepare for policy impacts — turning complexity into actionable strategy.
The Medicare Part D landscape is shifting fast. With IRA and H.R.1 driving formulary instability, manufacturers face rising deductibles, tighter utilization management, and new premium dynamics. Learn how Magnolia’s Part D Formulary Databook helps teams anticipate these changes and plan with confidence.
See how Magnolia Market Access helped a manufacturer overcome coding gaps, payer unfamiliarity, and site readiness challenges to launch the first FDA-approved therapy in a rare disease — creating a replicable, gold-standard access model.
Survey of 100 U.S. physicians uncovers key insights on how international HTA frameworks—especially Germany’s—undervalue chronic disease therapies. Explore the full infographic.
As states expand PDAB authority to set Upper Payment Limits (UPLs) on high-cost therapies, Magnolia Market Access surveyed physicians in Colorado, Maryland, Oregon, and Washington to understand how these policies may affect prescribing decisions, patient care, and clinical operations.
This issue brief provides insights into how 340B savings are being redirected by covered entities—particularly DSH hospitals—toward financial investments instead of patient care, underscoring the urgency of policy changes to realign the program with its mission.
In the June 2025 Navigating Market Access with Magnolia webinar, experts from across the market access ecosystem came together to examine the forces reshaping how manufacturers plan for pricing, reimbursement, and access.
On May 12, 2025, President Trump signed an executive order with the potential to significantly change the U.S. drug pricing and distribution system. Here is what we know about the Administration’s new Most Favored Nation (MFN) policy: